

**This communication should be viewed by:**

Facility/Practice staff  
Clinical staff

## Pharmaceutical Policies Updates Effective December 1, 2022

To keep our valued care delivery partners up to date, MVP Health Care® (MVP) is sharing Pharmaceutical Policy updates effective December 1, 2022.

To view all current MVP Medical policies, *Sign In* at [mvphealthcare.com](http://mvphealthcare.com) and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies are effective December 1, 2022 and will be available for viewing on or before November 1, 2022. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Crohn's Disease, Select Agents	Archived
Inflammatory Biologic Drug Therapy	Archived
Ulcerative Colitis	Archived
Infliximab	Updated
Ustekinumab	New
Proton Pump Inhibitor Therapy	Updated
Colony Stimulating Factors	Reviewed/No Changes
Mulpleta/Doptelet	Reviewed/No Changes
Erythropoiesis Stimulating Agents	Reviewed/No Changes
Hereditary Angioedema	Reviewed/No Changes
Irritable Bowel Syndrome	Updated
Gaucher Disease Type 1 Treatment	Updated
Select Chelating Agents	Updated
Hemophilia Factor	Reviewed/No Changes
Adakveo	Updated
Dojolvi	Updated

To view all communications, visit [mvphealthcare.com/FastFax](http://mvphealthcare.com/FastFax)

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.



Intestinal Antibiotics	Updated
Pharmacy Management Programs-External - Effective 9/1/2022	Updated
Medicare Part D Coverage Determination and Exception Policy	Updated
Transthyretin Mediated Amyloidosis	Updated
Spravato – Effective 8/11/2022	Updated
Ankylosing Spondylitis - Effective 1/1/2022	Archived
Rheumatoid Arthritis - Effective 1/1/2022	Archived
Psoriasis Drug Therapy	Archived
Psoriatic Arthritis Drug Therapy	Archived
Rinvoq	Archived
Ozanimod	New
Upadacitinib	New
Secukinumab	New
Etanercept	New
Adalimumab	New
Apremilast	New
Risankizumab	New
Tocacitinib	New
Guselkumab	New

To view all faxed messages, visit [mvphealthcare.com/FastFax](https://mvphealthcare.com/FastFax).

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

